Publications by authors named "Michael D Huband"

Claim this Profile
I
In vitro activity of sulopenem and comparator agents against US Enterobacterales clinical isolates collected during the SENTRY antimicrobial surveillance program in 2023.
Steven I Aronin, Michael D Huband, Holly Becker, Kelley A Fedler, Michael W Dunne

J Glob Antimicrob Resist· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Re-evaluation of penicillin and ceftriaxone MIC results to predict susceptibility to the oral cephalosporin, cefpodoxime, in clinical isolates from the United States according to CLSI guidelines (2019-2021).
Rodrigo E Mendes, Jessica V Pierce, Kelly Wright, Michael D Huband, Mariana Castanheira

J Clin Microbiol· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
In vitro activity of omadacycline against bacterial isolates from bone/joint infections and rare pathogens in the SENTRY antimicrobial surveillance program (2015-2023).
Michael D Huband, Paul R Rhomberg, Kelley A Fedler, Christopher Blankers, Diane Anastasiou

J Glob Antimicrob Resist· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Surveillance of omadacycline against 35,000 bacterial clinical isolates from the United States (2019-2023).
Michael D Huband, Kelley A Fedler, Rodrigo E Mendes, Helio S Sader, Diane Anastasiou

Diagn Microbiol Infect Dis· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Characterization of sulopenem antimicrobial activity using time-kill kinetics, synergy, post-antibiotic effect, and sub-inhibitory MIC effect methods against and isolates.
Joshua M Maher, Michael D Huband, Jill M Lindley, Paul R Rhomberg, Steven I Aronin

Microbiol Spectr· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Use of voriconazole to predict susceptibility and resistance to isavuconazole for using CLSI methods and interpretive criteria.
Marisa L Winkler, Paul R Rhomberg, Kelley A Fedler, Michael D Huband, Maura Karr

J Clin Microbiol· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
High Rates of Nonsusceptibility to Common Oral Antibiotics in Clinical Isolates From the United States (2019-2021).
Lalitagauri M Deshpande, Michael D Huband, Sarah Charbon, Mariana Castanheira, Rodrigo E Mendes

Open Forum Infect Dis· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sulbactam-durlobactam susceptibility test method development and quality control ranges for MIC and disk diffusion tests.
Sarah M McLeod, Nicole M Carter, Michael D Huband, Maria M Traczewski, Patricia A Bradford

J Clin Microbiol· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Determination of MIC Quality Control Ranges for Ceftibuten-Avibactam (Fixed 4 μg/mL), a Novel β-Lactam/β-Lactamase Inhibitor Combination.
Michael D Huband, Kelley A Fedler, Helio S Sader, Gregory G Stone, Mariana Castanheira

J Clin Microbiol· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
In vitro activity of sulopenem and comparator agents against Enterobacterales and anaerobic clinical isolates collected during the SENTRY Antimicrobial Surveillance Program.
Joshua M Maher, Michael D Huband, Christopher G Blankers, Sailaja Puttagunta, Steven I Aronin

J Antimicrob Chemother· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Antimicrobial activity of ceftibuten-avibactam against a global collection of Enterobacterales from patients with urinary tract infections (2021).
Helio S Sader, Cecilia G Carvalhaes, Michael D Huband, Rodrigo E Mendes, Mariana Castanheira

Eur J Clin Microbiol Infect Dis· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetic-Pharmacodynamic Target Attainment Analyses Evaluating Omadacycline Dosing Regimens for the Treatment of Patients with Community-Acquired Bacterial Pneumonia Arising from Streptococcus pneumoniae and Haemophilus influenzae.
Sujata M Bhavnani, Jeffrey P Hammel, Elizabeth A Lakota, Michael Trang, Justin C Bader, Michael D Huband

Antimicrob Agents Chemother· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of surfactants and other body fluids on in vitro activity of a novel β-lactamase inhibitor enmetazobactam in combination with cefepime against clinical isolates of Klebsiella pneumoniae.
Alina Nussbaumer-Pröll, Sabine Eberl, Adam Belley, Philipp Knechtle, Michael D Huband

J Antibiot (Tokyo)· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Antifungal Activity of Isavuconazole and Comparator Agents against Contemporaneous Mucorales Isolates from USA, Europe, and Asia-Pacific.
Cecilia G Carvalhaes, Paul R Rhomberg, Michael D Huband, Michael A Pfaller, Mariana Castanheira

J Fungi (Basel)· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Plain language summary: Does a person's age affect how common fungal infections are and how well drugs can kill the infections?
Michael A Pfaller, Cecilia G Carvalhaes, Sean DeVries, Michael D Huband, Mariana Castanheira

Future Microbiol· July 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Antimicrobial activity of dalbavancin against Gram-positive bacteria isolated from patients hospitalized with bloodstream infection in United States and European medical centers (2018-2020).
Helio S Sader, Mariana Castanheira, Michael D Huband, Dee Shortridge, Cecilia G Carvalhaes

Eur J Clin Microbiol Infect Dis· May 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Elderly versus nonelderly patients with invasive fungal infections: species distribution and antifungal resistance, SENTRY antifungal surveillance program 2017-2019.
Michael A Pfaller, Cecilia G Carvalhaes, Sean DeVries, Michael D Huband, Mariana Castanheira

Diagn Microbiol Infect Dis· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Activity of the Novel Aminomethylcycline KBP-7072 and Comparators against 1,057 Geographically Diverse Recent Clinical Isolates from the SENTRY Surveillance Program, 2019.
Michael D Huband, Jennifer D Thompson, Nabina D Gurung, Qingmei Liu, Li Li

Antimicrob Agents Chemother· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Surveillance of omadacycline activity tested against clinical isolates from the USA: report from the SENTRY Antimicrobial Surveillance Program, 2019.
Michael A Pfaller, Michael D Huband, Dee Shortridge, Robert K Flamm

J Glob Antimicrob Resist· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
activity of a novel aminomethylcycline antibacterial (KBP-7072), a third-generation tetracycline, against clinical isolates with molecularly characterized tetracycline resistance mechanisms.
Michael A Pfaller, Li Li, Qingmei Liu, Jay Zhang, Michael D Huband

JAC Antimicrob Resist· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Antimicrobial activity of manogepix, a first-in-class antifungal, and comparator agents tested against contemporary invasive fungal isolates from an international surveillance programme (2018-2019).
Michael A Pfaller, Michael D Huband, Robert K Flamm, Paul A Bien, Mariana Castanheira

J Glob Antimicrob Resist· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Frequency of occurrence and antimicrobial susceptibility of bacteria isolated from respiratory samples of patients hospitalized with pneumonia in Western Europe, Eastern Europe and the USA: results from the SENTRY Antimicrobial Surveillance Program (2016-19).
Helio S Sader, Jennifer M Streit, Cecilia G Carvalhaes, Michael D Huband, Dee Shortridge

JAC Antimicrob Resist· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
In vitro activity of iclaprim and comparator agents against Listeria monocytogenes clinical isolates from 2012 to 2018.
David B Huang, Leonard R Duncan, Yahse K Edah, Paul R Rhomberg, Robert K Flamm, Michael D Huband

J Glob Antimicrob Resist· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
In vitro activity of KHP-3757 (a novel LpxC inhibitor) and comparator agents against recent and molecularly characterized Pseudomonas aeruginosa isolates from a global surveillance program (2017-2018).
Michael D Huband, Jill M Lindley, Rodrigo E Mendes, Kelley A Fedler, Vincent J Benn

Diagn Microbiol Infect Dis· December 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Omadacycline invitro activity against a molecularly characterized collection of clinical isolates with known acquired tetracycline resistance mechanisms.
Rodrigo E Mendes, Michael D Huband, Jennifer M Streit, Mariana Castanheira, Robert K Flamm

Diagn Microbiol Infect Dis· July 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis